New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 25, 2012
05:55 EDTAON, AON, GT, GT, COL, COL, NWL, NWL, MCO, MCO, LYB, LYB, MRK, MRK, LM, LM, IPG, IPG, CVH, CVH, CMCSA, CMCSA, WY, WYCompanies reporting Before the Market Open on Friday, October 26
Notable companies reporting before the opening bell include Aon (AON), Comcast (CMCSA), Coventry Health Care (CVH), Interpublic Group of Companies (IPG), Legg Mason (LM), Merck & Co (MRK), LyondellBasell Industries (LYB), Moodys (MCO), Newell Rubbermaid (NWL), Rockwell Collins (COL), The Goodyear Tire & Rubber (GT) and Weyerhaeuser (WY).
News For AON;CMCSA;CVH;IPG;LM;MRK;LYB;MCO;NWL;COL;GT;WY From The Last 14 Days
Check below for free stories on AON;CMCSA;CVH;IPG;LM;MRK;LYB;MCO;NWL;COL;GT;WY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 16, 2014
06:27 EDTCMCSANBCUniversal planning digital video push
Subscribe for More Information
05:54 EDTCMCSATime Warner Cable upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo upgraded Time Warner Cable (TWC) to Outperform on expectations the merger with Comcast (CMCSA) will get approved. Wells raised the low end of its price target range for shares to $140-$160 from $132.50-$160.
April 15, 2014
08:23 EDTMRKLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTMRKLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:26 EDTCMCSAReport: Comcast raised advertised basic TV rates 68% over 4 years, NY Post says
Subscribe for More Information
06:32 EDTMRKPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
18:00 EDTMRKU.S. FDA approves Merck's GRASTEK
Subscribe for More Information
13:19 EDTCMCSANetflix's streaming speeds on Comcast jumped, The Verge reports
Subscribe for More Information
06:08 EDTMRKMerck volatility elevated into Q1 and outlook
Subscribe for More Information
April 11, 2014
17:01 EDTAONAon plc raises annual dividend 43%
Aon plc announced that its Board of Directors has authorized a 43% increase to its annual cash dividend paid quarterly on Aon's outstanding Class A Ordinary Shares. Consistent with the increase in the dividend, the Board of Directors has declared a quarterly cash dividend of 25c per share on outstanding Class A Ordinary Shares, reflecting a 43% increase from 17.5c per share. The dividend is payable May 15 to shareholders of record on May 1.
10:35 EDTIPGHigh option volume stocks: HZNP NI IPG CYTR SNV NBR
Subscribe for More Information
05:22 EDTMRKMerck says Hepatitis C combination therapy shows antiviral activity
Subscribe for More Information
April 10, 2014
17:44 EDTMRKMerck stock could return 20%, Barron's says
Subscribe for More Information
09:37 EDTMRKActive equity options trading on open
Active equity options trading on open according to Track Data: SIRI RAD AAPL AMZN AA FB TSLA MRK CVX C
09:21 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTMRKXencor Merck receives milestone payment from Merck for using XmAb antibody
Xencor (XNCR) announced that the company has received a milestone payment from Merck (MRK), through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb antibody engineering intellectual property. Under the terms of the agreement signed in June 2013, Xencor granted Merck a non-exclusive license to certain Xencor patents for use in an undisclosed product, as well as an option to license the same intellectual property for future products. Xencor received an upfront payment and continues to receive annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates, as well as royalties on sales of any potential products that may result from this agreement.
07:58 EDTLMLegg Mason reports Assets Under Management $702B as of March 31
Subscribe for More Information
07:49 EDTCMCSALawmakers concerned over Internet share of combined Comcast-TWC, LAT says
During merger review proceedings, legislators on the Senate Judiciary Committee expressed particular concern about the 40% nationwide share of the Internet market that would be held by a combined Comcast (CMCSA) and Time Warner Cable (TWC) if the two are permitted to merge, reported The Los Angeles Times. Reference Link
07:21 EDTCMCSAHulu's head of original programming development to leave company, AdWeek says
Subscribe for More Information
05:27 EDTMRKMerck announces data from C-WORTHy study
Merck announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus, or HCV, NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection, or GT1. In an interim analysis of treatment-na´ve, non-cirrhotic patients administered a 12-week regimen of MK-5172/MK-8742, with and without ribavirin, or RBV, a sustained viral response, or SVR, was observed in 98% of patients administered MK-5172/MK-8742 alone and 94% in those administered MK-5172/MK-8742 plus RBV.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use